Helix Acquisition CORP Ii Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
BridgeBio Oncology Therapeutics, Inc. reports a pro rata distribution of shares by Helix Holdings II LLC to its members, impacting ownership percentages.
BridgeBio Pharma LLC and BridgeBio Pharma, Inc. have acquired a 17.5% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc. following a business combination.
BridgeBio Oncology Therapeutics, formerly Helix Acquisition Corp. II, completed its business combination with TheRas, Inc., leading to significant shareholding changes for key investors including Bihua Chen.
SCHEDULE 13D/A: Helix Acquisition Corp. II Announces Definitive Business Combination with BridgeBio Oncology Therapeutics, Securing $260M PIPE Investment
Helix Acquisition Corp. II has entered into a definitive business combination agreement with BridgeBio Oncology Therapeutics, Inc., which includes a $260 million PIPE investment and a planned domestication to Delaware.